vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and NORTH EUROPEAN OIL ROYALTY TRUST (NRT). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.2M, roughly 1.7× NORTH EUROPEAN OIL ROYALTY TRUST). On growth, NORTH EUROPEAN OIL ROYALTY TRUST posted the faster year-over-year revenue change (329.5% vs -10.2%).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

North European Oil Royalty Trust is a publicly traded royalty trust holding overriding royalty interests in North Sea oil and gas producing properties. It earns revenue from its assets' production sales, distributing nearly all net income to unitholders regularly, with no active drilling or exploration operations.

IRD vs NRT — Head-to-Head

Bigger by revenue
IRD
IRD
1.7× larger
IRD
$3.9M
$2.2M
NRT
Growing faster (revenue YoY)
NRT
NRT
+339.7% gap
NRT
329.5%
-10.2%
IRD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IRD
IRD
NRT
NRT
Revenue
$3.9M
$2.2M
Net Profit
$1.9M
Gross Margin
Operating Margin
Net Margin
87.2%
Revenue YoY
-10.2%
329.5%
Net Profit YoY
53.0%
581.3%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
NRT
NRT
Q1 26
$2.2M
Q4 25
$3.9M
Q3 25
$3.1M
Q2 25
$2.9M
Q1 25
$4.4M
$519.4K
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
Net Profit
IRD
IRD
NRT
NRT
Q1 26
$1.9M
Q4 25
Q3 25
$-17.5M
Q2 25
$-7.4M
Q1 25
$-8.2M
$285.5K
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
Operating Margin
IRD
IRD
NRT
NRT
Q1 26
Q4 25
Q3 25
-269.9%
Q2 25
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
Net Margin
IRD
IRD
NRT
NRT
Q1 26
87.2%
Q4 25
Q3 25
-566.9%
Q2 25
-257.5%
Q1 25
-187.5%
55.0%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
EPS (diluted)
IRD
IRD
NRT
NRT
Q1 26
Q4 25
Q3 25
$-0.25
Q2 25
$-0.12
Q1 25
$-0.24
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
NRT
NRT
Cash + ST InvestmentsLiquidity on hand
$45.1M
$3.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.3M
Total Assets
$50.2M
$3.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
NRT
NRT
Q1 26
$3.9M
Q4 25
$45.1M
Q3 25
$30.8M
Q2 25
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
Stockholders' Equity
IRD
IRD
NRT
NRT
Q1 26
Q4 25
$15.3M
Q3 25
$6.0M
Q2 25
$17.5M
Q1 25
$5.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
Total Assets
IRD
IRD
NRT
NRT
Q1 26
$3.9M
Q4 25
$50.2M
Q3 25
$36.1M
Q2 25
$38.7M
Q1 25
$48.2M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
NRT
NRT
Operating Cash FlowLast quarter
$-35.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
NRT
NRT
Q1 26
Q4 25
$-35.3M
Q3 25
$-6.2M
Q2 25
$-10.3M
Q1 25
$-9.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons